SBI Securities’s Black Diamond Therapeutics BDTX Stock Holding History

SBI Securities’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$191	Hold	103	–	–	﹤0.01%	3341
2026 Q1	$219	Hold	103	–	–	﹤0.01%	3186
2025 Q4	$250	Sell	103 -4	-4%	-$14	﹤0.01%	3141
2025 Q3	$406	Sell	107 -49	-31%	-$143	﹤0.01%	3054
2025 Q2	$387	Sell	156 -192	-55%	-$370	﹤0.01%	3068
2025 Q1	$539	Buy	348 +195	+127%	+$409	﹤0.01%	2842
2024 Q4	$327	Buy	+153	New	+$438	﹤0.01%	3051

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

SBI Securities's BDTX Position: Q2 2026 in Review

SBI Securities held its Black Diamond Therapeutics (BDTX) position steady in Q2 2026 at 103 shares worth $191. The position accounts for ﹤0.01% of the portfolio, ranked #3341.

SBI Securities first reported a position in BDTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $539 in Q1 2025. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

SBI Securities held 103 shares of Black Diamond Therapeutics worth $191 as of Q2 2026.
SBI Securities left its Black Diamond Therapeutics share count unchanged in Q2 2026.
Black Diamond Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3341 holding.
SBI Securities first reported a position in Black Diamond Therapeutics in Q4 2024 and has held it in 7 quarters since.
SBI Securities's Black Diamond Therapeutics position peaked at $539 in Q1 2025.
96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.